An observational study in Diabetes and Diabetes Mellitus, sponsored by MidAtlantic Retina. Completed at 1 site in United States. Open to participants aged 18 Minutes and older. Per ClinicalTrials.gov, last updated 2017-02-23.
Sponsored by MidAtlantic Retina · Observational
You are being asked to be in a research study to determine blood levels and vitreous levels of compounds called thrombospondin 1 (TSP1) and pigment epithelium derived factor (PEDF). These compounds exists naturally in your body.
The hypothesis tested here is that diabetic patients that express the higher molecular weight pigment epithelium-derived factor (PEDF) isoform have lower thrombospondin-1 (TSP1) level and, as a result, are at a greater risk for the development of more severe diabetic retinopathy.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 90 is below the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →MidAtlantic Retina is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with diabetes mellitus who are undergoing pars plana vitrectomy for any reason
Exclusion Criteria:
Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.
Biological: Blood draw
3-4 tablespoons of blood will be drawn, one time.
Level of thrombospondin (TSP1) and pigment epithelium derived factor (PEDF) in the vitreous and plasma
Your voluntary participation in this study may help determine how different TSP1 and PEDF levels correlate with diabetic eye disease.
Time frame: up to 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MidAtlantic Retina